Serum Prolactin and Bone Mineral Density in Schizophrenia: A Systematic Review
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
The relationship between serum prolactin and bone mineral density (BMD) in schizophrenia is unclear. We conducted a literature review of databases from inception until December 2018 for cross-sectional, case-control, prospective and retrospective studies analyzing correlations between serum prolactin and BMD measured using dual energy X-ray absorptiometry or quantitative ultrasound at any skeletal site in people with schizophrenia. Data was summarized with a best evidence synthesis. This review identified 15 studies (1 longitudinal study, 10 cross-sectional and 4 case-control studies; 1,360 individuals with a psychotic disorder; mean age 45.1 ± 9.4 [standard deviation] years, female 742 [54.6%], mean illness duration 17.7 ± 11.3 years) assessing the relationship between serum prolactin and BMD in schizophrenia. There was a statistically significant inverse correlation between serum prolactin and BMD identified in eight of the studies (53% of all studies), suggesting mixed evidence for an association between serum prolactin and BMD. Of those studies which identified a significant inverse correlation between serum prolactin and BMD (n = 5), 152 (52.1%) of patients were treated with prolactin raising antipsychotics, compared to 197 (48.1%) of patients in those studies which did not identify a significant correlation between prolactin and BMD. Available studies cannot resolve the link between excess prolactin and reduced BMD in schizophrenia. Future studies should be longitudinal in design and combine measures of serum prolactin along with other risk factors for reduced BMD such as smoking and vitamin D and sex hormone levels in assessing the relationship between prolactin and BMD in schizophrenia.
Abstract
The relationship between serum prolactin and bone mineral density (BMD) in schizophrenia is unclear. We conducted a literature review of databases from inception until December 2018 for cross-sectional, case-control, prospective and retrospective studies analyzing correlations between serum prolactin and BMD measured using dual energy X-ray absorptiometry or quantitative ultrasound at any skeletal site in people with schizophrenia. Data was summarized with a best evidence synthesis. This review identified 15 studies (1 longitudinal study, 10 cross-sectional and 4 case-control studies; 1,360 individuals with a psychotic disorder; mean age 45.1 ± 9.4 [standard deviation] years, female 742 [54.6%], mean illness duration 17.7 ± 11.3 years) assessing the relationship between serum prolactin and BMD in schizophrenia. There was a statistically significant inverse correlation between serum prolactin and BMD identified in eight of the studies (53% of all studies), suggesting mixed evidence for an association between serum prolactin and BMD. Of those studies which identified a significant inverse correlation between serum prolactin and BMD (n = 5), 152 (52.1%) of patients were treated with prolactin raising antipsychotics, compared to 197 (48.1%) of patients in those studies which did not identify a significant correlation between prolactin and BMD. Available studies cannot resolve the link between excess prolactin and reduced BMD in schizophrenia. Future studies should be longitudinal in design and combine measures of serum prolactin along with other risk factors for reduced BMD such as smoking and vitamin D and sex hormone levels in assessing the relationship between prolactin and BMD in schizophrenia.
참고문헌 (59)
- Kanis JA, "Diagnosis of osteoporosis and assessment of fracture risk", Lancet, 359, pp.1929~1936 (2002)
- Cooper C, "Hip fractures in the elderly : a world-wide projection", Osteoporos Int, 2, pp.285~289 (1992)
- Riggs BL, "The worldwide problem of osteoporosis: insights afforded by epidemiology", Bone, 17(5 Suppl), pp.505S~511S (1995)
- Stubbs B, "A meta-analysis of prevalence estimates and moderators of low bone mass in people with schizophrenia", Acta Psychiatr Scand, 130, pp.470~486 (2014)
- Stubbs B, "Schizophrenia and the risk of fractures : a systematic review and comparative meta-analysis", Gen Hosp Psychiatry, 37, pp.126~133 (2015)
- Gomez L, "Lower bone mineral density at the hip and lumbar spine in people with psychosis versus controls : a comprehensive review and skeletal site-specific meta-analysis", Curr Osteoporos Rep, 14, pp.249~259 (2016)
- Lally J, "Hyperprolactinaemia in first episode psychosis-a longitudinal assessment", Schizophr Res, 189, pp.117~125 (2017)
- Bushe C, "A review of the association between antipsychotic use and hyperprolactinaemia", J Psychopharmacol, 22(2 Suppl), pp.46~55 (2008)
- Pouwels S, "Antipsychotic use and the risk of hip", femur fracture : a population-based case-control study, 2009, pp.20, 1499~1506
- Howard L, "Risk of hip fracture in patients with a history of schizophrenia", Br J Psychiatry, 190, pp.129~134 (2007)
- Bolton JM, "Risk of low bone mineral density associated with psychotropic medications and mental disorders in postmenopausal women", J Clin Psychopharmacol, 31, pp.56~60 (2011)
- Liperoti R, "Conventional or atypical antipsychotics and the risk of femur fracture among elderly patients: results of a case-control study", J Clin Psychiatry, 68, pp.929~934 (2007)
- Sørensen HJ, "Schizophrenia, antipsychotics and risk of hip fracture : a population-based analysis", Eur Neuropsychopharmacol, 23, pp.872~878 (2013)
- Bakken MS, "Antipsychotic drugs and risk of hip fracture in people aged 60 and older in Norway", J Am Geriatr Soc, 64, pp.1203~1209 (2016)
- Chien-Yu Chen, "Effects of Antipsychotics on Bone Mineral Density in Patients with Schizophrenia: Gender Differences", Clinical Psychopharmacology and Neuroscience, 14(3), pp.238~249 (2016), 대한정신약물학회
- 이태영, "Bone Density in Chronic Schizophrenia with Long-Term Antipsychotic Treatment: Preliminary Study", PSYCHIATRY INVESTIGATION, 7(4), pp.278~284 (2010), 대한신경정신의학회
- Takahashi T, "The impact of prolactin-raising antipsychotics on bone mineral density in patients with schizophrenia : findings from a longitudinal observational cohort", Schizophr Res, 147, pp.383~386 (2013)
- Becker D, "Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients", J Clin Psychiatry, 64, pp.761~766 (2003)
- Meaney AM, "Bone mineral density changes over a year in young females with schizophrenia : relationship to medication and endocrine variables", Schizophr Res, 93, pp.136~143 (2007)
- O’Keane V, "Antipsychotic drugs : a new risk factor for osteoporosis in young women with schizophrenia", J Clin Psychopharmacol, 25, pp.26~31 (2005)
- Lin CH, "Clozapine protects bone mineral density in female patients with schizophrenia", Int J Neuropsychopharmacol, 15, pp.897~906 (2012)
- Lin CH, "Sex-specific factors for bone density in patients with schizophrenia", Int Clin Psychopharmacol, 30, pp.96~102 (2015)
- Tseng PT, "Bone mineral density in schizophrenia: an update of current meta-analysis and literature review under guideline of PRISMA", Medicine (Baltimore), 94, pp.e1967~ (2015)
- De Hert M, "Relationship between antipsychotic medication, serum prolactin levels and osteoporosis", osteoporotic fractures in patients with schizophrenia : a critical literature review, 2016, pp.15, 809~823
- Stroup DF, "Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group", JAMA, 283, pp.2008~2012 (2000)
- Moher D, "Preferred reporting items for systematic reviews and metaanalyses : the PRISMA statement", Ann Intern Med, 151, pp.264~269 (2009)
- American Psychiatric Association, "Diagnostic and statistical manual of mental disorders: DSM-IV-TR" (2000), American Psychiatric Association
- World Health Organization (WHO), "The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines", WHO, ~ (1992)
- Frost ML, "Quantitative ultrasound and bone mineral density are equally strongly associated with risk factors for osteoporosis", J Bone Miner Res, 16, pp.406~416 (2001)
- Guglielmi G, "Quantitative ultrasond in the assessment of osteoporosis", Eur J Radiol, 71, pp.425~431 (2009)
- Robertson A, "Bone quantification", Orthop Trauma, 31, pp.326~329 (2017)
- World Health Organization, "Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO study group", World Health Organ Tech Rep Ser, 843, pp.1~129 (1994)
- Kanis JA, "Assessment of fracture risk and its application to screening for postmenopausal osteoporosis : synopsis of a WHO report", Osteoporos Int, 4, pp.368~381 (1994)
- "Interventions directed to professionals" (2011)[URL]
- Wang M, "Effects of antipsychotics on bone mineral density and prolactin levels in patients with schizophrenia : a 12-month prospective study", Hum Psychopharmacol, 29, pp.183~189 (2014)
- Bergemann N, "High bone turnover but normal bone mineral density in women suffering from schizophrenia", Psychol Med, 38, pp.1195~1201 (2008)
- Bulut SD, "The effect of antipsychotics on bone mineral density and sex hormones in male patients with schizophrenia", Psychiatr Danub, 28, pp.255~262 (2016)
- Howes OD, "Bone mineral density and its relationship to prolactin levels in patients taking antipsychotic treatment", J Clin Psychopharmacol, 25, pp.259~261 (2005)
- Hummer M, "Osteoporosis in patients with schizophrenia", Am J Psychiatry, 162, pp.162~167 (2005)
- Jung DU, "Prevalence of bone mineral density loss in Korean patients with schizophrenia : a cross-sectional study", J Clin Psychiatry, 67, pp.1391~1396 (2006)
- Kishimoto T, "Antipsychotic-induced hyperprolactinemia inhibits the hypothalamo-pituitary-gonadal axis and reduces bone mineral density in male patients with schizophrenia", J Clin Psychiatry, 69, pp.385~391 (2008)
- Liang Y, "Factors associated with decreased bone mineral density in postmenopausal women with schizophrenia", Clin Interv Aging, 11, pp.153~157 (2016)
- Renn JH, "Effects of plasma magnesium and prolactin on quantitative ultrasound measurements of heel bone among schizophrenic patients", BMC Musculoskelet Disord, 11, pp.35~ (2010)
- Rey-Sánchez P, "Ultrasound bone mass in schizophrenic patients on antipsychotic therapy", Hum Psychopharmacol, 24, pp.49~54 (2009)
- Sugawara N, "No association between bone mass and prolactin levels among patients with schizophrenia", Hum Psychopharmacol, 26, pp.596~601 (2011)
- Abraham G, "Bone mineral density and prolactin associations in patients with chronic schizophrenia", Schizophr Res, 59, pp.17~18 (2003)
- Hallahan B, "Bone mineral density and general health of long-term residential psychiatric inpatients", Ir J Psychol Med, 25, pp.95~99 (2008)
- Jihyeon Kim, "Menstrual Irregularities and Sex Hormones in Female Patients Treated with Conventional Antipsychotics for more than 5 Years", Clinical Psychopharmacology and Neuroscience, 8(1), pp.21~25 (2010), 대한정신약물학회
- Kinon BJ, "Bone loss associated with hyperprolactinemia in patients with schizophrenia", Clin Schizophr Relat Psychoses, 7, pp.115~123 (2013)
- Lally J, "Clinical correlates of vitamin D deficiency in established psychosis", BMC Psychiatry, 16, pp.76~ (2016)
- Lally J, "Vitamin D and clinical symptoms in First Episode Psychosis(FEP) : a prospective cohort study", Schizophr Res, 204, pp.381~388 (2019)
- Crews M, "Vitamin D deficiency in first episode psychosis : a case-control study", Schizophr Res, 150, pp.533~537 (2013)
- Savvidis C, "Obesity and bone metabolism", Hormones(Athens), 17, pp.205~217 (2018)
- Shin-ya Watanabe, "Association Study of Fat-mass and Obesity-associated Gene and Body Mass Index in Japanese Patients with Schizophrenia and Healthy Subjects", Clinical Psychopharmacology and Neuroscience, 10(3), pp.185~189 (2012), 대한정신약물학회
- Daniel Thomson, "Tobacco Use in Bipolar Disorder", Clinical Psychopharmacology and Neuroscience, 13(1), pp.1~11 (2015), 대한정신약물학회
- de Leon J, "A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors", Schizophr Res, 76, pp.135~157 (2005)
- González-Blanco L, "Prolactin concentrations in antipsychotic-naïve patients with schizophrenia and related disorders : a meta-analysis", Schizophr Res, 174, pp.156~160 (2016)
- Stewart A, "Long-term fracture prediction by DXA and QUS : a 10-year prospective study", J Bone Miner Res, 21, pp.413~418 (2006)
- Nayak S, "Meta-analysis : accuracy of quantitative ultrasound for identifying patients with osteoporosis", Ann Intern Med, 144, pp.832~841 (2006)